PBC Data From AASLD: Part 3
Selected FXR Agonist PBC Studies: Conference Coverage of AASLD

Released: December 13, 2023

Kris V. Kowdley
Kris V. Kowdley, MD, FAASLD, FACP, FACG

Activity

Progress
1
Course Completed

During the 2023 American Association for the Study of Liver Diseases conference, exciting and important results from many primary biliary cholangitis (PBC) clinical trials were reported, including 3 late-breaking studies on the PPAR-δ agonist seladelpar, the dual PPAR agonist elafibranor, and the combination of the FXR agonist obeticholic acid and a fibrate.

In this episode, Kris V. Kowdley MD, FAASLD, FACP, FACG, discusses topline results from several of these studies and more, including:

  • A combination of 3 studies—HEROES, COBALT, and COBALT EC—that evaluated the real-world effectiveness and safety of second-line therapy in PBC where OCA was added to the treatment regimen of people with PBC with an incomplete response to ursodeoxycholic acid
  • Lessons learned from a long-term outcomes study of people with PBC
  • Results from 2 phase II studies of obeticholic acid plus bezafibrate in people with PBC who did not respond to or were intolerant of ursodeoxycholic acid